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Mutations in the tumor suppressor gene p53 have been reported as occurring prevalently
in a wide range of human tumors. Detection of a mutated p53 is thought to provide useful
information for the clinical management of colorectal neoplasm. In this study, we used
polymerase chain reaction/single-strand conformation polymorphism (PCR/SSCP) and
sequencing analysis to rapidly screen for mutations in p53 in colorectal cancer in Taiwan.
Genomic DNA was purified from colorectal cancer specimens obtained from 80 patients at
a teaching hospital in southern Taiwan. Primer sets were designed to amplify fragments
within exons 4–8 of p53. We found p53 mutations in 38 of 80 patients. This is the first
identification of a mutation at codon 143 of p53 in colorectal cancer in Taiwan. In addition,
we found two insertions in exon 5 of p53. The p53 mutation rate among colorectal tumors
in Taiwan, found in this study, is 43%. The results indicate that p53 mutation is not sig-
nificantly associated with tumor grade, age, or gender (p > 0.05). We found that two-fifths
of colorectal cancer patients in Taiwan have a p53 mutation, which could be used as a marker
of colorectal cancer.
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Oncogenic activity or loss of tumor suppressor gene
function resulting from genetic alterations such as
mutation, insertion, or deletion is prevalent in tumor
cells and ultimately causes abnormal gene expression.
The p53 gene, a well-characterized tumor suppressor
gene, is the most frequently altered gene in human
cancers, with mutations in approximately 60% of car-
cinomas [1–3]. It is localized in region p13.1 of chro-
mosome 17, a region frequently lost in tumor tissues
[1,4]. The p53 protein plays a critical role in the preven-
tion of tumor formation, although it is not required for
normal cell growth. It can induce cell cycle arrest,
DNA repair, inhibition of angiogenesis, differentiation,
or apoptosis in response to oncogenic cellular stress,
including carcinogen-induced DNA damage, abnor-
mal proliferative stimulation, and hypoxia. For
example, it binds to specific DNA sequences and then
activates expression of inhibitors of cell cycle-
dependent protein kinase complexes such as WAF1
and GADD45 in response to DNA damage. Expression
of these proteins causes the cell cycle to stop at the
G0/G1 phase.
Inactivation of p53 is considered to be a late event
involved in the malignant transformation of colorectal
adenoma to cancer [2,5]. It involves a two-step mecha-
nism consisting of a point mutation in one allele and
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the loss of another allele, in agreement with Knudson’s
two-hit hypothesis [6]. Mutations in p53 most prob-
ably occur within the highly conserved region, exons
4–8, and renders p53 non-functional [7]. In most cases,
p53 mutations are associated with a loss of p53’s abil-
ity to be transactivated not only by the binding of viral
or endogenous antigens of p53 genes but also by the
response elements of one or both alleles [8–10]. On the
other hand, p53 modulates responsiveness to different
drugs or treatments [10].
Adenocarcinoma of the colon provides the best
model for understanding the genetic alteration in
tumors because the histologic progression of this tumor
has been reported to correlate with specific gene
mutations. Single-strand conformation polymorphism
(SSCP) has been used to detect point mutations and
allelic loss in many genes, particularly p53 [11–13].
The purpose of the present study was to clarify the p53
mutations in Taiwanese patients with colorectal cancer.
We rapidly screened 20 colorectal cancer samples from
southern Taiwan using SSCP [14] and sequencing in
order to detect p53 mutations in exons 4–8. The results
suggest that genetic changes in p53 play an important
role in colorectal cancer.
MATERIALS AND METHODS
Tissue samples
Colorectal tissue specimens (20 fresh tissue and 60
paraffin blocks) were obtained from 80 patients un-
dergoing colorectal cancer surgery in Military
Kaohsiung General Hospital. Specimens were grossly
diagnosed by a pathologist; fresh tissue specimens
were snap-frozen immediately and stored at –80ºC
until used.
DNA extraction from paraffin blocks
Three to five 4 µm thick paraffin tissue sections were
collected in a 1.5 ml microtube. After adding xylene 1
ml and incubating at 70ºC for 10 minutes, samples
were centrifuged at 10,000 rpm for 5 minutes at room
temperature (RT, 25ºC); the xylene was then discarded.
Ethanol (95%, 1 ml) was added to the microtube and
mixed well before incubation for 3 minutes at RT,
followed by centrifugation at 10,000 rpm for 5 minutes
at RT; the ethanol was then discarded. The pellet was
either dried in vacuum for 6 minutes or in the air until
the ethanol had completely evaporated.
DNA extraction from tumor tissue
DNA was extracted using the DNeasyTM Tissue Kit
(QIAGEN, Valencia, CA, USA) according to the
manufacturer’s instructions. Briefly, tumor tissue was
digested with 0.5 mg/ml proteinase K in 400 µl cell-
lysis solution for 24 hours at 55ºC until the tissue was
completely lysed. After adding 200 µl absolute ethanol,
the mixture was transferred onto the DNeasy mini-
column and centrifuged for 1 minute at 8,000 rpm. The
DNeasy mini-column was washed with the 500 µl
washing buffer provided in the kit and centrifuged for
1 minute at 8,000 rpm. Finally, the DNA was eluted
into a clean 1.5 ml microcentrifuge tube using 100 µl
water.
PCR/SSCP analysis
The highly conserved regions of p53, exons 4–8, were
each amplified separately using intronic oligonucleo-
tide primers (Table 1). PCR was performed using the
hot-start technique in a final volume of 25 µl reaction
buffer containing 50 mM KCl, 1.5 mM MgCl2, 10 mM
Tris-HCl (pH 9.0 at RT), 2 µM ethylenediaminetetraace-
tic acid (EDTA), 0.1 mM dithiothreitol (DTT), 1%
glycerol, 200 µM each of dATP, dCTP, and dTTP, 50
µM dGTP, 150 µM 7-deaza-dGTP, 10 pmol of each
primer, 1.5 U Taq polymerase, and 60 ng genomic
DNA in 0.5 ml polypropylene microtubes. PCR was
performed for 35 cycles: 30 seconds of denaturation at
94ºC, 30 seconds of annealing at 55ºC, and 30 seconds
of extension at 72ºC. Amplicons (8 µl) were mixed with
8 µl of 2x sample buffer (2x TBE, 0.1% bromophenol
blue, 0.1% xlyene cyanol, 10% Ficoll 400), then sepa-
rated on a 2.5% non-denaturing agarose gel
(AMRESCO, Inc., Solon, OH, USA) and visualized
using ethidium bromide.
For SSCP analysis, 4 µl of the PCR product was
diluted in 4 µl loading buffer (95% formamide, 20 mM
EDTA, 0.05% bromophenol blue, 0.5 xylene cyanol),
heated at 95ºC for 3 minutes and cooled on ice before
loading onto the electrophoresis gel. Electrophoretic
analysis was carried out using a Genephor Electro-
phoresis Unit (Amersham Pharmacia Biotech, Uppsala,
Sweden) using the manufacturer’s GeneGel Excel
12.5/24 kit, at 5ºC for 3 to 4 hours, 25 mA, 15 W, and
200 V. Finally, gels were stained in a Hoefer Auto-
mated Gel Stainer (Amersham Pharmacia) using
the PlusOne DNA Silver Staining Kit (Amersham
Pharmacia)  according to the manufacturer’s
instructions.
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DNA sequencing analysis
Sequencing was performed using original p53 PCR
products for all 80 patients. Where SSCP indicated the
presence of a mutation not detected by sequencing,
the variant band was selected from the gel and re-
amplified. Sequencing primers were the same as those
used for PCR. The PCR product was purified using
QIAquick Purification Columns (QIAGEN, Hilden,
Germany) and sequenced using Taq cycle sequencing
with a Dye Terminator Cycle-Sequencing Ready-Re-
action Kit (ABI Prism, Perkin Elmer, Branchburg, NJ,
USA) according to the manufacturer’s instructions.
Sequence analysis was performed using the ABI
PRISMTM 310 Genetic Analyzer (Perkin Elmer). To
avoid false-positive results due to polymerase errors,
PCR, SSCP, and sequence analysis was repeated.
Statistical analysis
Regression analysis was used to determine the varia-
tion in sex, age, and Duke’s classification with p53
gene mutation.
RESULTS
The study sample consisted of 80 patients (male: 53,
female: 27). The mean age was 66.8 years (range, 25 to
90 years). At the time of initial diagnosis, 11 tumors
were classified as Duke’s A, 34 as Duke’s B, and 35 as
Duke’s C. Our results indicate that p53 mutation was
not significantly associated with tumor grade, age,
and gender (p > 0.05, Table 2). Samples showed either
abnormal or no abnormal bands on PCR/SSCP (Figure
1). The results of direct sequencing were compatible
with those of SSCP analysis (Figure 2), with no muta-
tions in the sequence data without abnormal bands on
SSCP analysis. Relative mutations in p53 are summa-
rized in Table 3; codon mutations were identified by
comparing our results with sequences in Gene Bank.
To our knowledge, the mutations at codons 72, 143,
and 243 have not previously been reported in colorectal
cancer in Taiwan. Mutations at codon 157 from GTC
(Val) to GTA (Val), and codon 255 from ATC (Ile) to
ATA (Ile) in exon 5, and codon 276 from TTG (Leu)
to CTG (Leu) in exon 8, led to no change in the p53
protein. Among intron mutations, a G to T substitu-
tion at site 14168 (intron 7) was found in seven of
the 20 fresh tissue specimens (35%). The site of
mutation was possibly dependant on colorectal cancer
(Table 4).
DISCUSSION
Using PCR/SSCP analysis and sequencing of exons
4–8, we have demonstrated that 34 of 80 patients (42.5%)
have p53 mutations. These include mutations at: codon
72, detected in 18 out of 80 patients (22.5%); codon 143,
detected in six patients (7.5%); codon 157, detected in
two patients (2.5%); codon 243, detected in seven
patients (8.75%); codon 255, detected in three patients
(3.75%); and codons 175, 181, and 192 detected in one
patient each (1.25%). There were two insertions in
exon 5, in codons 181 to 182, with CGCTGC changed to
CGCATGC, and codons 152 to 153, with CCCGCC
changed to CCCCGCC.
Table 1. p53 polymerase chain reaction primers used in this study
p53 exon Primer name Primer sequence Size Position
Exon 4 P4F 5’-CAACGTTCTGGTAAGGACAA-3’ 486 bp 11918–12403
P4R 5’-GCCTAAGGGTGAAGAGGAA-3’
Exon 5 P5F 5’-TCACTTGTGCCCTGACTT-3’ 297 bp 13008–13304
P5R 5’-GAGGAATCAGAGGCCTGG-3’
Exon 6 P6F 5’-GAGACGACAGGGCTGGTT-3’ 198 bp 13258–13455
P6R 5’-GAGACCCCAGTTGCAAAC-3’
Exon 7 P7F 5’-CCAAGGCGCACTGGCCTC-3’ 213 bp 13957–14169
P7R 5’-GCGGCAAGCAGAGGCTGG-3’
Exon 8 P8F 5’-CCTTACTGCCTCTTGCTTC-3’ 237 bp 14413–14649
P8R 5’-TGAATCTGAGGCATAACT-3’
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The tumor suppressor gene, p53, causes cell cycle
arrest and apoptosis in response to a variety of cellular
damage [2]. Mutation within the DNA binding region
of p53 results in expression of a dysfunctional p53 that
has been reported in most human tumors including
gastric, breast, and colorectal tumors [7]. In this study,
we investigated p53 mutations in 80 colorectal carci-
nomas in Taiwan.
In colorectal neoplasms, abnormalities of p53 most
likely occur as a late event during the transition from
adenoma to adenocarcinoma [1]. p53 is a nuclear pro-
tein with a short half-life and is hardly expressed in
normal cells. In cancer cells, mutated p53 reportedly
acquires an elongated half-life, leading to its accumu-
lation [2]. It has been shown that up to 30% of tumors
may accumulate non-mutated p53 [15]. Data demon-
strate that most colorectal carcinomas with loss of 17p
are associated with a p53 mutation [16,17]. However,
other studies have indicated that a 17p loss is not
necessarily associated with p53 mutation in other
tumors, such as breast cancer and medulloblastoma. A
more detailed analysis of the commonly deleted re-
gion suggests the presence of another tumor suppres-
sor gene on 17p13.3 [18,19]. Therefore, abnormalities
of p53 in colon neoplasms should be screened using
PCR/SSCP analysis to clarify its role in colon
tumorigenesis.
There is some controversy on allele frequencies in
patients with colorectal cancer. The p53 status of each
tumor was analyzed by PCR and sequencing of exons
Table 2. Demographic data of 80 colorectal cancer patients with relation to p53 mutations
Item Cases Mutants Mean p53
n n (%) Chi-squared or t p
Sex 1.08 0.30
   M 53 24 (45)
   F 27 10 (37)
Age (yr) 66.8 –0.05 0.96
Duke’s classification 2.83 0.24
   A 11 3 (27)
   B 34 13 (38)
   C 35 18 (51)
Total 80 34 (43)
Figure 1. PCR/SSCP analysis of exon 4 of p53 from colorectal
cancer tissues. Arrows indicate shift bands in lanes 7 (FT4)
and 10 (FT1). FT = fresh tissue.
Figure 2. Confirmation of mutation by direct sequencing of the
PCR product:  (A) 18 cases revealed a G-to-C point mutation at
the second base of codon 72; (B) seven cases revealed an A-to-C
point mutation at the second base of codon 243.
A
B
M 1 2 3 4 5 6 7 8 9 10
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5 to 8 (codons 126–306) [20]. Five of 31 (16%) patients
had mutations in p53, of which two were nonsense
mutations, two were transition mutations, and one
was a frameshift deletion mutation. Most p53 muta-
tions were found in exon 5. We examined the allele
frequencies of this polymorphism but could not find
evidence that it was associated with a statistical pre-
disposition to colorectal cancer. From our studies, we
found that most p53 mutations in the Taiwanese popu-
lation are in exon 4: 20% in codon 72 (exon 4), 7% in
codon 143 (exon 5) and 8% in codon 243 (exon 7). Our
data indicated that one-third of colorectal cancers in
Taiwanese patients had mutations in codons 72, 143,
and 243. PCR/SSCP is suitable for p53 mutation screen-
ing in colorectal cancer.
A number of studies have reported an association
between p53 mutations and human tumorigenesis.
Eight of 18 (44%) cases tested showed a variant band
indicative of a mutation in exons 5 to 8, and seven of
these cases (88%) stained positive for p53 [21]. More
recently, Tang and co-workers have reported that the
p53 mutation rate among colorectal cancers in Taiwan
is lower (31%) than those in various other populations,
whereas the frameshift mutation rate (20%) was the
highest [22]. They have also demonstrated 57 (31%)
p53 mutations in 181 primary colorectal cancer pa-
tients in the Chang Gung Medical Center in northern
Taiwan. Our study demonstrated 34 mutations (43%)
in p53 among 80 colorectal cancer patients. Table 5
shows the hotspot codons for p53 mutations in Tai-
wanese and other populations, confirmed by our study.
The Val143 mutation in our study was more frequent
(7%) than has been reported by others (0.5%) [23].
Different p53 mutants vary in their tumorigenic proper-
ties [24]. Mutation at Val143 leads to extensive confor-
mational change and renders the protein unstable, but
its role in tumorigenesis remains to be elucidated [24].
More interestingly, the higher Val143 mutation fre-
quency in southern Taiwan than in northern Taiwan
suggests that different Taiwanese populations have
different genetic backgrounds. To minimize false-
positive results in our study, all mutations found by
SSCP were confirmed by sequencing an independent
PCR product. Differences in p53 mutational frequency
between younger and older patients may reflect a
different set of somatically acquired mutations associ-
ated with breast cancer in the premenopausal and
postmenopausal age group [22]. In our study, there
was no difference in p53 mutational frequency be-
tween younger and older colorectal cancer patients.
We found that the base substitutions at codons 72,
143, and 243 were similar among populations with
various risks for colorectal cancer in southern Taiwan.
Among the populations studied, colorectal cancer in
southern Taiwan — which is a high-risk area for this
type of cancer — had a higher p53 mutation rate (43%)
Table 3. Mutations in p53 in colon cancer patients in Taiwan
Case ID Exon Codon Codon change Nucleotide change Amino acid change
FT1 4* 72 CGC to CCC G to C Arg to Pro
FT20 5† 143 GTG to GCG T to C Val to Ala
FT11 5* 155 ACC to AAC C to A Thr to Asn
FT15 5 157 GTC to GTN C to N Val to Val‡
FT18 5* 175 CGC to CAC G to A Arg to His
FT6 5 181 CGC to CCC G to C Arg to Pro
FT2 5* 192 CAG to CAT G to  T Gln to His
FT18 6* 212 ACT to CCT A to C Thr to Pro
FT2 7* 235 AAC to ATG AC to TG Asn to Leu
FT9 7† 243 ATG to CTG A to C Met to Leu
FT3 7 248 CGG to TGG C to T Arg to Trp
FT1 7 255 ATC to ATA C to A Ile to Ile‡
FT12 8* 276 TTG to CTG T to C Leu to Leu‡
FT7 5 181–182 CGCATGC Insert A Truncated
FT11 5 152–153 CCCCGCC Insert C Truncated
*New colon cancer mutation in this study; †mutation in colon cancer first reported in this study; ‡conservative mutation. ID = identification;
FT = fresh tissue.
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than colorectal cancer in northern Taiwan (31%; Table
4). The distinct p53 mutation pattern may reflect
different etiologic factors involved in colorectal
carcinogenesis in Taiwan. However, normal intestinal
tissue was always excluded from the tumor samples.
Some studies, including our own, have shown a
great number of p53 mutations in colorectal cancer
patients. Molecular assessment of surgical margins
using p53 mutations enables the selection of head and
neck squamous cell carcinoma patients at high risk of
tumor recurrence, but tumor RNA seems, at present,
to be a more specific biomolecule for analysis than
tumor DNA [25]. In conclusion, the simple analysis of
p53 using PCR/SSCP is suitable for screening p53
abnormalities in colorectal cancer. We hope that
detection of p53 mutations can be used as a marker for
early diagnosis of colorectal cancer.
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